Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Nevro Corp (NVRO – Research Report) and Apellis Pharmaceuticals (APLS – Research Report).
Sarepta Therapeutics (SRPT)
Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics on May 7 and set a price target of $145.00. The company’s shares closed last Thursday at $132.30.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $167.31, implying a 25.6% upside from current levels. In a report issued on May 1, Citi also maintained a Buy rating on the stock with a $172.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nevro Corp (NVRO)
Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Nevro Corp on May 8 and set a price target of $16.00. The company’s shares closed last Thursday at $10.51, close to its 52-week low of $10.07.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
Currently, the analyst consensus on Nevro Corp is a Hold with an average price target of $16.30, representing a 61.2% upside. In a report issued on May 7, Wells Fargo also maintained a Hold rating on the stock with a $13.00 price target.
Apellis Pharmaceuticals (APLS)
In a report issued on May 8, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $52.00. The company’s shares closed last Thursday at $42.52.
According to TipRanks.com, Suvannavejh has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $78.17, implying an 82.9% upside from current levels. In a report issued on May 8, Wells Fargo also maintained a Hold rating on the stock with a $57.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
